Los futuros del Ibex 35 dudan pero se decantan por el verde; por encima de los 14.100 puntos
Yahooarrow_outwardIBEX 35 HOY: a cuánto abre el índice de la Bolsa de Madrid este miércoles 9 de julio
El Cronistaarrow_outwardEl IBEX 35 se dispara con los bancos y roza máximos del año gracias al optimismo comercial
TradingViewarrow_outwardGrifols' stock market rises due to positive earnings prospects - Diari ARA
Diari ARAarrow_outwardShort Seller Gotham Beats Most of Grifols’ Defamation Claims - Bloomberg Law News
Bloomberg Law Newsarrow_outwardGrifols’s Family Blood Is Thicker Than Water - Bloomberg
Bloombergarrow_outwardGrifols Case Shows It Paid Family-Linked Entity More for Plasma - Mint
Mintarrow_outwardOsborne Clarke advises Grifols on delisting offer and delisting from stock exchange of Biotest - Osborne Clarke
Osborne Clarkearrow_outwardGrifols' takeover bid for Biotest, accepted by 2.11% of ordinary shares with voting rights (1.05% of capital) - The Corner .eu
The Corner .euarrow_outwardAshurst advises Biotest on the public delisting offer by GRIFOLS and its delisting from the Frankfurt Stock Exchange - Ashurst
Ashurstarrow_outwardGlobal Moves: Iberdrola, ACS, Grifols, And Aena's Strategic Expansions - Finimize
Finimizearrow_outwardXL-protein grants worldwide license to Grifols - European Pharmaceutical Manufacturer
European Pharmaceutical Manufacturerarrow_outwardGrifols Completes Acquisition of Biotest Shares Following Delisting - TipRanks
TipRanksarrow_outwardGrifols Sues Gotham Over Defamation Free Speech and Stock Fallout - Lawyer Monthly
Lawyer Monthlyarrow_outwardXL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewswire
GlobeNewswirearrow_outwardXL-protein and Grifols ink global biopharma licensing deal - The Pharma Letter
The Pharma Letterarrow_outwardMason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting - Business Wire
Business Wirearrow_outwardUS court proceeds with Grifols defamation case against Gotham City, but narrows scope - Yahoo Finance
Yahoo Financearrow_outwardFDA clears Grifols’ application for dry eye disease treatment - Clinical Trials Arena
Clinical Trials Arenaarrow_outwardFDA clears Grifols' Investigational New Drug application for immunoglobulin drops for the treatment of DED - Ophthalmology Times
Ophthalmology Timesarrow_outwardGrifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
Seeking Alphaarrow_outwardIND Application Cleared for Phase II Trial of Grifols’ Dry Eye Disease Drops - PharmTech
PharmTecharrow_outwardGrifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’ - SelectScience
SelectSciencearrow_outwardGrifols - drugdiscoverytrends.com
Drugdiscoverytrends.comarrow_outwardBrookfield revives €7bn takeover talks with Grifols as shares surge 11% - Private Equity Insights
Private Equity Insightsarrow_outwardSpanish pharma company Grifols' shares up on Brookfield talk - Reuters
Reutersarrow_outwardGrifols Chair Symposium: Translating Science into the Clinic - Hospital Clínic Barcelona
Hospital Clínic Barcelonaarrow_outwardThe importance of time: Grifols seeks biomarkers for early diagnosis of disease - pharmaphorum
Pharmaphorumarrow_outwardGrifols IVIG Shows Promise for Post-Polio Syndrome - Contract Pharma
Contract Pharmaarrow_outwardGrifols shares soar as Spanish drugmaker expects to boost revenue and free cash flow - The Globe and Mail
The Globe and Mailarrow_outwardGrifols collaborates with startup FcR Therapeutics to develop autoimmune therapies - PharmaTimes
PharmaTimesarrow_outwardSpain accused of 'scaring off and intimidating' short-sellers in Grifols case - IFR Asia
IFR Asiaarrow_outwardGA_P advises on Grifols’ €1.3 billion bond issue - Iberian Lawyer
Iberian Lawyerarrow_outwardThe Michael J Fox Foundation for Parkinson’s Research awards grant to Grifols for pioneering study - Drug Target Review
Drug Target Reviewarrow_outwardGrifols garners $21M grant from Michael J. Fox Foundation to hunt for early Parkinson's disease biomarkers - Fierce Biotech
Fierce Biotecharrow_outwardSpain: Grifols ends acquisition discussions with Brookfield - Investors in Healthcare
Investors in Healthcarearrow_outwardGrifols shares sink after Brookfield walks away from €6.45bn offer - Financial Times
Financial Timesarrow_outwardGrifols faces old issues as Brookfield walks away from takeover bid - FirstWord Pharma
FirstWord Pharmaarrow_outwardGrifols rejects Brookfield’s ‘undervalued’ $6.8bn bid - Private Equity Wire
Private Equity Wirearrow_outwardPlasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer - Fierce Pharma
Fierce Pharmaarrow_outwardCourt accepts complaint against Gotham for spreading 'biased and misleading' information about Grifols - Catalan News
Catalan Newsarrow_outward
Grifols close
- 2025-07-10 01:40 event
- 41 sourceslanguage
- 200+ ads_click
- 2 weeks ago schedule